ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases

Shen, Kunlu; Gu, Yu; Wang, Yu; Lu, Yajie; Ni, Yueyan; Zhong, Huanhiuan; Shi, Yi; Su, Xin*南方医科大学; 南京大学; 1
Therapeutic Advances in Drug Safety2022-10DOI: 10.1177/20420986221127503
7被引10阅读
引用收藏
分享

摘要

Aims: The gene polymorphism of voriconazole metabolism-related liver enzyme is notable in East Asia population. It casts a significant influence on the rational use of voriconazole. We conducted this study to investigate the relationship between steady-state voriconazole trough concentration (C-trough) and adverse effects (AEs), especially hepatotoxicity. @@@ Methods: We conducted a real-world study in the Jinling Hospital from January 2015 to June 2020. A total of 140 patients receiving voriconazole were enrolled in this study. The determination and scoring of voriconazole-associated hepatotoxicity were performed according to the Roussel Uclaf Causality Assessment Method scoring scale and the severity of hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE). @@@ Results: Elevated steady-state voriconazole C-trough with concomitant AEs are the most common reason for dose adjustments during treatment. Compared with the group without any AEs, voriconazole C-trough was significantly higher in the hepatotoxicity and neurotoxicity groups, and the incidence of both events showed an overall increasing trend with increasing voriconazole C-trough. Hepatotoxicity occurred in 66.7% of patients within 7 days of the first dose of voriconazole and 94.4% within 15 days of the dose. Steady-state voriconazole C-trough >3.61 mg/l was associated with an increased incidence of hepatotoxicity (area under the curve = 0.645, p = 0.047). Logistic regression analysis showed that timely voriconazole dose adjustment was a predictor of attenuated hepatotoxicity after adjustment for confounders, but hepatotoxicity was not associated with voriconazole C-trough measured at a single time point. @@@ Conclusion: Hepatotoxicity and neurotoxicity correlate with voriconazole C-trough, and dose reduction in patients with elevated steady-state voriconazole C-trough may prevent hepatotoxicity. In patients with early occurrence of hepatotoxicity, initial therapeutic drug monitoring (TDM) might predict the risk of hepatotoxicity. Follow-up TDM may be necessary to predict late onset hepatotoxicity.

学科与关键词

关键词
hepatotoxicitysafetyvoriconazolevoriconazote trough concentration
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Drug Safety
发表日期
2022-10
卷期
第 13 卷
DOI
10.1177/20420986221127503
期刊等级
3区
成果收录
SCIE
资助标注
Natural Science Foundation of China project [82270019, 82070011]; Key Project of Jiangsu Commission of Health [K2019004]

作者

  • S

    Shen, Kunlu (第一作者)

    1 · southern med univ

  • G

    Gu, Yu

    nanjing med univ

查看全部 8 位作者收起作者
  • W

    Wang, Yu

    nanjing univ

  • L

    Lu, Yajie

    nanjing univ

  • N

    Ni, Yueyan

    nanjing med univ

  • Z

    Zhong, Huanhiuan

    nanjing univ

  • S

    Shi, Yi

    nanjing univ

  • S

    Su, Xin (通讯)

    nanjing univ · nanjing med univ · 1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417